Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04071769 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

StatusCompleted
PhasePhase 2
Started2020-08-03
View on ClinicalTrials.gov ↗
The purpose of this study is being done to determine whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments. Participants will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyper-polarized 129 Xenon. The subjects will have this initial study prior to initiation of IPF therapies. Then the participants will have repeat studies at 3, 6 and 12 months following the initiation of therapy.

Amendment history 2 changes detected by DataLookout

2026-08-25
notable
Trial completed
2026-08-25
minor
Completion moved earlier: 2029-09-30 → 2025-10-17
Trial Details
NCT Number NCT04071769
Lead Sponsor Duke University
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 34 participants
Start Date 2020-08-03
Primary Completion 2024-10-17 (estimated)
Study Completion 2025-10-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-24